摘要
Tumor hypoxia is a pathophysiologic outcome of disrupted microcirculation with inadequate supply of oxygen, leading to enhanced proliferation, epithelial-mesenchymal transition (EMT), metastasis, and chemo-resistance. Epigenetic changes induced by hypoxia are well documented, and they lead to tumor progression. Recent advances show that DNA demethylation mediated by the Ten-eleven translocation (TET) proteins induces major epigenetic changes and controls key steps of cancer development. TET enzymes serve as 5mC (5-methylcytosine)-specific dioxygenases and cause DNA demethylation. Hypoxia activates the expression of TET1, which also serves as a co-activator of HIF-1a transcriptional regulation to modulate HIF-1a downstream target genes and promote epithelial-mesenchymal transition. As HIF is a negative prognostic factor for tumor progression, hypoxia-activated prodrugs (HAPs) may provide a favorable therapeutic approach to lessen hypoxia-induced malignancy.
| 原文 | 英語 |
|---|---|
| 文章編號 | 24 |
| 期刊 | Journal of Clinical Medicine |
| 卷 | 5 |
| 發行號 | 2 |
| DOIs | |
| 出版品狀態 | 已出版 - 04 02 2016 |
| 對外發佈 | 是 |
文獻附註
Publisher Copyright:© 2016 by the authors; licensee MDPI, Basel, Switzerland.
UN SDG
此研究成果有助於以下永續發展目標
-
SDG3 健康與福祉
指紋
深入研究「Hypoxia, epithelial-mesenchymal transition, and tet-mediated epigenetic changes」主題。共同形成了獨特的指紋。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver